Radiation with helical tomotherapy before stem cell transplant
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and are currently doing induction treatment and getting ready to collect stem cells for your own transplant
- You can follow the study’s birth control (contraception) rules during the trial
- Your performance status is ECOG 2 or better (you can generally do daily activities with limited assistance)
- Your blood tests and liver/kidney markers are high enough (bilirubin, ALT, AST within limits; kidney function okay), and your neutrophils and platelets meet minimum levels
- You collected at least 2 million CD34+ stem cells per kilogram (part of stem cell mobilization for transplant)
- You are expected to live more than 3 months and can provide informed consent (you or a close family member)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.